ID: ALA3753625

Max Phase: Preclinical

Molecular Formula: C8H12N2O2

Molecular Weight: 168.20

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  Cc1nc(CO)c(C)nc1CO

Standard InChI:  InChI=1S/C8H12N2O2/c1-5-7(3-11)10-6(2)8(4-12)9-5/h11-12H,3-4H2,1-2H3

Standard InChI Key:  DLCVYRQRINMKBM-UHFFFAOYSA-N

Associated Targets(non-human)

Heart 1007 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 168.20Molecular Weight (Monoisotopic): 168.0899AlogP: 0.08#Rotatable Bonds: 2
Polar Surface Area: 66.24Molecular Species: NEUTRALHBA: 4HBD: 2
#RO5 Violations: 0HBA (Lipinski): 4HBD (Lipinski): 2#RO5 Violations (Lipinski): 0
CX Acidic pKa: 13.69CX Basic pKa: 0.87CX LogP: -1.57CX LogD: -1.57
Aromatic Rings: 1Heavy Atoms: 12QED Weighted: 0.66Np Likeness Score: -0.22

References

1. Zhu HH, Chen YQ, Cheng D, Li W, Wang TL, Wen HM, Chen L, Liu J..  (2016)  Synthesis and positive inotropic activity evaluation of liguzinediol metabolites.,  26  (3): [PMID:26725025] [10.1016/j.bmcl.2015.12.072]

Source